Abstract
Chromosomal translocations involving BCL6 gene are frequent in human B-cell lymphomas. Chromosomal breaks preferentially occur within a 3-kb region containing the first exon and intron. Recent reports have revealed that internal deletions or point mutations also are common in this region, suggesting that structural alteration of this region may be a crucial event in the development of lymphomas. In this study, we identified two regions in the BCL6 gene that negatively regulate BCL6 expression. One region, ES, is located within the first exon between nucleotides +472 and +543, and a second region, IS, is located between +783 and +918 of the first intron. A consensus nucleotide sequence for the binding of the BCL6 protein itself was found within the ES region. An electrophoretic mobility shift assay and a co-transfection experiment using a BCL6 expression vector showed that transcription of the BCL6 gene was negatively regulated by the BCL6 gene product. The IS region which is included in the regions commonly deleted in B-cell lymphomas had a silencer activity. Structural alterations of these two regions may play roles in the deregulated expression of the BCL6 gene in B-cell lymphomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
276,54 € per year
only 5,53 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout



Similar content being viewed by others
References
Albagli O, Dhordain P, Bernardin F, Quief S, Kerkaert JP and Leprince D. . 1996 Biochem. Biophys. Res. Commun. 220: 911–915.
Baron BW, Nucifora G, McCabe N, Espinosa RI, Le Beau MM and McKeithan TW. . 1993 Proc. Natl. Acad. Sci. USA 90: 5262–5266.
Bernardin F, Collyn dHM, Quief S, Bastard C, Leprince D and Kerckaert JP. . 1997 Oncogene 14: 849–855.
Capello D, Carbone A, Pastore C, Gloghini A, Saglio G and Gaidano G. . 1997 Br. J. Haematol. 99: 168–170.
Cattoretti G, Zhang J, Cleary AM, Lederman S, Gaidano G, Carbone A and Chaganti RSK. . 1997 Blood 90: 175a.
Chang CC, Ye BH, Chaganti RS and Dalla-Favera R. . 1996 Proc. Natl. Acad. Sci. USA 93: 6947–6952.
Chen WY, Butler M, Rao PH, Chaganti SR, Louie DC, Dalla-Favera R and Chaganti RSK. . 1998 Oncogene 17: 1717–1722.
Deweindt C, Albagli O, Bernardin F, Dhordain P, Quief S, Lantoine D, Kerckaert JP and Leprince D. . 1995 Cell Growth Differ. 6: 1495–1503.
Gaidano G, Carbone A, Pastore C, Capello D, Migliazza A, Gloghini A, Roncella S, Ferrarini M, Saglio G and Dalla-Favera R. . 1997 Blood 89: 3755–3762.
Kawamata N, Miki T, Ohashi K, Suzuki K, Fukuda T, Hirosawa S and Aoki N. . 1994 Biochem. Biophys. Res. Commun. 204: 366–374.
Kerckaert JP, Deweindt C, Tilly H, Quief S, Lecocq G and Bastard C. . 1993 Nature Genet. 5: 66–70.
Klaus GG, Choi MS, Lam EW, Johnson-Leger C and Cliff J. . 1997 Int. Rev. Immunol. 15: 5–31.
Liang R, Chan WP, Kwong YL, Chan AC, Xu WS and Srivastava G. . 1998 Cancer. Genet. Cytogenet. 102: 110–113.
Migliazza A, Martinotti S, Chen W, Fusco C, Ye BH, Knowles DM, Offit K, Chaganti RS and Dalla-Favera R. . 1995 Proc. Natl. Acad. Sci. USA 92: 12520–12524.
Miki T, Kawamata N, Hirosawa S and Aoki N. . 1994 Blood 83: 26–32.
Nakamura Y, Miki T, Miura I, Hashimoto K, Miura A, Akimoto K, Hirosawa S, Saito K, Enokihara H, Furusawa S and Shishido H. . 1996 Leukemia 10: 658–661.
Nakamura Y, Saito K and Furusawa S. . 1999 Br. J. Haematol. 105: 274–277.
Ohashi K, Miki T, Hirosawa S and Aoki N. . 1995 Biochem. Biophys. Res. Commun. 214: 461–467.
Pasqualucci L, Migliazza A, Fracchiolla N, William C, Neri A, Baldini L, Chaganti RSK, Klein U, Kuppers R, Rajewsky K and Dalla-Favera R. . 1998 Proc. Natl. Acad. Sci. USA 95: 11816–11821.
Seyfert VL, Allman D, He Y and Staudt LM. . 1996 Oncogene 12: 2331–2342.
Shen HM, Peters A, Baron B, Zhu XD and Storb U. . 1998 Science 280: 1750–1752.
Ye BH, Lista F, Lo CF, Knowles DM, Offit K, Chaganti RS and Dalla-Favera R. . 1993 Science 262: 747–750.
Acknowledgements
We thank Dr Patrick Matthius for providing us with pKappaLucE and pH2BLucE, and Dr Hiroshi Itoh for pEFLac. We also thank Miss Kaori Okada for technical support. This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kikuchi, M., Miki, T., Kumagai, T. et al. Identification of negative regulatory regions within the first exon and intron of the BCL6 gene. Oncogene 19, 4941–4945 (2000). https://doi.org/10.1038/sj.onc.1203864
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203864
Keywords
This article is cited by
-
Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells
Scientific Reports (2019)
-
MEF2B is a member of the BCL6 gene transcriptional complex and induces its expression in diffuse large B-cell lymphoma of the germinal center B-cell-like type
Laboratory Investigation (2019)
-
A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements
Pathology & Oncology Research (2016)
-
Novel CTCF binding at a site in exon1A of BCL6 is associated with active histone marks and a transcriptionally active locus
Oncogene (2015)
-
TGF-β and retinoic acid induce the microRNA miR-10a, which targets Bcl-6 and constrains the plasticity of helper T cells
Nature Immunology (2012)


